Respiratory disorders, Medicines planning
2 results
Applied filters
The licence and supporting evidence for omalizumab biosimilar
14 November 2025We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).
Preparing to use omalizumab biosimilar
19 September 2025Omalizumab biosimilars are expected soon. We offer general information and implementation advice.